Moleculin Biotech (MBRX)
NASDAQ:MBRX
Top Page
Moleculin Biotech
(NASDAQ:MBRX)
Select Model
Select Model
Rating:46Neutral
Price Target:
$2.50
▼(-1.96% Downside)
Action:ReiteratedDate:03/24/26
Score is held down primarily by weak financial performance (no revenue, ongoing losses and cash burn) and bearish technical signals (below key moving averages with negative MACD). Offsetting these somewhat are positive corporate developments around Annamycin/MIRACLE trial progress and reduced near-term delisting risk; valuation signals are limited given negative earnings and no dividend data.
Positive Factors
Pivotal MIRACLE trial progress
Reaching the 45th subject triggers an interim unblinding mid-2026 in an adaptive Phase 2B/3 design. A positive interim readout would materially de-risk Annamycin’s registration pathway, enabling partnering, accelerated development decisions, and clearer commercialization planning over the next 2–6 months.
Negative Factors
Zero revenue and persistent losses
The company remains pre-commercial with no product revenue and sustained operating losses. Over the medium term this means continued dependence on clinical success to create intrinsic value; absent positive trial outcomes, the business lacks recurring revenue to fund operations or prove commercial viability.
Read all positive and negative factors
Positive Factors
Negative Factors
Pivotal MIRACLE trial progress
Reaching the 45th subject triggers an interim unblinding mid-2026 in an adaptive Phase 2B/3 design. A positive interim readout would materially de-risk Annamycin’s registration pathway, enabling partnering, accelerated development decisions, and clearer commercialization planning over the next 2–6 months.
Read all positive factors
Moleculin Biotech (MBRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$13.61M
Dividend YieldN/A
Average Volume (3M)2.74M
Price to Earnings (P/E)0.6
Beta (1Y)1.42
Revenue GrowthN/A
EPS Growth79.31%
CountryUS
Employees17
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)2.61
Shares Outstanding5,336,350
10 Day Avg. Volume1,958,319
30 Day Avg. Volume2,738,732
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)2.61
Price to Sales (P/S)0.00
P/FCF Ratio-1.72
Enterprise Value/Market Cap-0.39
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit90.70
Enterprise Value/Ebitda0.21
Forecast
1Y Price Target
$21.00Price Target Upside723.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-6.91
Revenue Forecast (FY)N/A
Moleculin Biotech Business Overview & Revenue Model
Company Description
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the tre...
How the Company Makes Money
null...
Moleculin Biotech Earnings Call Summary
Earnings Call Date:May 14, 2025
(Q1-2025)
| % Change Since: |
Next Earnings Date:May 07, 2026
Earnings Call Sentiment Positive
The earnings call reflects significant progress in clinical trials and regulatory approvals, particularly for Annamycin. New patents and drug names bolster future market positioning. However, financial constraints and potential EU approval delays pose challenges.Positive Updates
Phase 3 MIRACLE Trial Progress
The Phase 3 MIRACLE trial for Annamycin has officially started with the first patient treated, and 38 sites selected worldwide. The European Medicines Agency has approved the trial in all nine countries requested.
Negative Updates
Financial Runway and Need for Additional Funding
The company ended the quarter with $8 million in cash, which will only run operations into the third quarter of this year, necessitating a $15 million raise.
Read all updates
Q1-2025 Updates
Positive
Negative
Phase 3 MIRACLE Trial Progress
The Phase 3 MIRACLE trial for Annamycin has officially started with the first patient treated, and 38 sites selected worldwide. The European Medicines Agency has approved the trial in all nine countries requested.
Read all positive updates
Company Guidance
During the Moleculin Biotech First Quarter 2025 Update Conference Call, several key metrics and guidance were discussed. The company announced the initiation of the Phase 3 MIRACLE trial for Annamycin, with 38 sites selected globally and the first patient already treated. The European Medicines Agency provided approval for the trial across nine EU countries, marking a significant milestone. Moleculin also revealed additional patent protections for Annamycin, extending its composition of matter protection into at least 2040. They highlighted the progress of their MB-107 clinical trial for advanced soft tissue sarcoma and the investigator-sponsored trial of WP1066, which has recruited seven patients at Northwestern University. Financially, Moleculin ended the quarter with $8 million in cash and anticipates needing to raise approximately $15 million to fund operations into the first quarter of 2026. They aim to unblind data from the first 45 patients in the MIRACLE trial by the end of 2025, which they believe will be pivotal for potential new drug approval. Their market cap stands at over $14 million, with 14.1 million shares outstanding and a three-month average trading volume of nearly 6 million shares per day.Moleculin Biotech Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
46
Neutral
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -90.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -25.01M | -26.52M | -29.50M | -30.51M | -22.80M |
| Net Income | -33.56M | -21.76M | -29.77M | -29.02M | -15.89M |
Balance Sheet | |||||
| Total Assets | 22.13M | 16.93M | 38.22M | 57.42M | 84.09M |
| Cash, Cash Equivalents and Short-Term Investments | 8.88M | 4.28M | 23.55M | 43.15M | 70.90M |
| Total Debt | 359.00K | 478.00K | 574.00K | 451.00K | 159.00K |
| Total Liabilities | 7.12M | 10.95M | 12.14M | 5.23M | 5.10M |
| Stockholders Equity | 15.01M | 5.98M | 26.07M | 52.19M | 78.99M |
Cash Flow | |||||
| Free Cash Flow | -22.73M | -23.88M | -24.23M | -27.71M | -18.97M |
| Operating Cash Flow | -22.73M | -23.86M | -24.10M | -27.64M | -18.95M |
| Investing Cash Flow | 0.00 | -13.00K | -124.00K | -67.00K | -19.00K |
| Financing Cash Flow | 27.28M | 4.63M | 4.65M | -23.00K | 74.72M |
Moleculin Biotech Technical Analysis
Neutral
2.55
Price Trends
2.88
Negative
4.35
Negative
8.58
Negative
Market Momentum
-0.08
Negative
53.86
Neutral
70.61
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MBRX, the sentiment is Neutral. The current price of 2.55 is above the 20-day moving average (MA) of 2.25, below the 50-day MA of 2.88, and below the 200-day MA of 8.58, indicating a neutral trend. The MACD of -0.08 indicates Negative momentum. The RSI at 53.86 is Neutral, neither overbought nor oversold. The STOCH value of 70.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for MBRX.
Moleculin Biotech Risk Analysis
Moleculin Biotech disclosed 58 risk factors in its most recent earnings report. Moleculin Biotech reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Moleculin Biotech Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $13.61M | 0.63 | ― | ― | ― | 79.31% | |
46 Neutral | $76.00M | -5.32 | -71.26% | ― | 185.71% | 79.03% | |
43 Neutral | $72.55M | -9.60 | -353.36% | ― | -10.36% | 42.36% | |
42 Neutral | $4.44M | -0.46 | -68.21% | ― | ― | ― |
* Healthcare Sector Average
MBRX
Moleculin Biotech
2.55
-17.44
-87.25%
IBIO
Ibio
2.16
0.96
80.00%
INO
Inovio Pharmaceuticals
1.06
-0.55
-34.16%
AKTX
Akari Therapeutics
3.92
-38.88
-90.84%
LNAI
Lunai Bioworks
0.41
-3.36
-89.02%
Moleculin Biotech Corporate Events
Business Operations and StrategyProduct-Related Announcements
Moleculin Advances MIRACLE Trial, Prepares Interim AML Readout
Positive
Mar 23, 2026
On March 23, 2026, Moleculin Biotech announced enrollment of the 45th subject in its pivotal Phase 2B/3 MIRACLE trial of AnnAraC, a combination of Annamycin and cytarabine, for adults with relapsed or refractory acute myeloid leukemia. This marks ...
Business Operations and StrategyRegulatory Filings and Compliance
Moleculin Biotech Updates Investors with New Corporate Presentation
Neutral
Mar 19, 2026
On March 19, 2026, Moleculin Biotech, Inc. reported that it is using a new corporate presentation, which has been posted on its website for stakeholders. The materials were furnished in connection with a Current Report on Form 8-K, underscoring an...
Business Operations and StrategyPrivate Placements and Financing
Moleculin Biotech Raises Capital via Inducement Warrant Agreements
Neutral
Feb 20, 2026
On February 19, 2026, Moleculin Biotech entered into inducement agreements with certain warrant holders, prompting the exercise of existing warrants to buy up to 2,122,652 shares at $3.90 each, which is expected to generate gross proceeds of about...
Business Operations and StrategyRegulatory Filings and Compliance
Moleculin Biotech Issues New Investor Corporate Presentation
Neutral
Feb 18, 2026
On February 18, 2026, Moleculin Biotech, Inc. reported that it is using a new corporate presentation, which has been posted on its website for investor and stakeholder viewing. The materials were furnished under a current report framework rather t...
Business Operations and StrategyProduct-Related Announcements
Moleculin Reports Positive Progress in MIRACLE AML Trial
Positive
Feb 18, 2026
On February 18, 2026, Moleculin Biotech reported progress in its pivotal global Phase 2B/3 MIRACLE trial of Annamycin plus cytarabine in adults with relapsed or refractory acute myeloid leukemia after a single prior induction therapy. As of Februa...
Business Operations and Strategy
Moleculin Gains Japanese Patent Allowance for Annamycin
Positive
Feb 17, 2026
On February 17, 2026, Moleculin Biotech, Inc. announced that the Japan Patent Office issued a notice of allowance for a patent application covering methods of reconstituting and preparing liposomal Annamycin for intravenous use. The allowed claims...
Private Placements and FinancingShareholder Meetings
Moleculin Biotech Shareholders Approve Warrant Share Issuance
Neutral
Feb 5, 2026
At a special meeting of stockholders held on February 5, 2026, Moleculin Biotech’s shareholders approved the potential issuance of up to 2,610,823 shares of common stock upon exercise of certain warrants that were issued on December 11, 2025...
Business Operations and StrategyRegulatory Filings and Compliance
Moleculin Biotech Updates Investors with New Corporate Presentation
Neutral
Jan 20, 2026
On January 20, 2026, Moleculin Biotech, Inc. used a new corporate presentation, made available on its website, as part of its investor communications, while clarifying in a regulatory filing that the materials were being furnished rather than file...
Business Operations and StrategyProduct-Related Announcements
Moleculin Highlights Non-Cardiotoxic Profile of Lead Annamycin Drug
Positive
Jan 13, 2026
On January 13, 2026, Moleculin Biotech reported that an independent expert’s review of data from 90 subjects treated with its lead drug candidate Annamycin across five clinical trials in AML and STS found no evidence of cardiotoxicity, even ...
Business Operations and StrategyProduct-Related Announcements
Moleculin Biotech advances Annamycin AML Phase 3 program
Positive
Jan 12, 2026
On January 12, 2026, Moleculin Biotech outlined an accelerated development and clinical outlook centered on its lead drug Annamycin and its STAT3 inhibitor WP1066, highlighting a pivotal global Phase 3 AML trial, new indications, and multiple exte...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.